Comparison Of Leading COVID-19 Vaccine Candidates For U.S. Vaccine Distribution

Updated March 2021

This quick reference guide compares the following leading COVID-19 vaccines and vaccine candidates in terms of administration, efficacy, ancillary supplies, and other key factors.

Vaccine Efficacy
  • Pfizer/BioNTech: 95%
  • Moderna: 94.5%
  • AstraZeneca: Testing showed 90% for initial half-strength dose, 62% for two standard-dose shots
  • Johnson & Johnson: 72%
  • Novavax: Unknown
  • Sanofi/GlaxoSmithKline: In 2020, Sanofi/GSK announced disappointing results for people over 50 and planned to start a new Phase 2 trial in 2021 with different formulation

Download the PDF for further details such as vaccine names, vaccine types, distribution, storage, and more.

Download PDF

See Also

Infectious Diseases
Market Report
Influenza Vaccine Market Report
Read More >
Market Insights
Market Report
Vaccine Market Report
Read More >
Flu Vaccine
Webinar Recording
Preparing for the 2023-2024 Flu Season
Read More >